{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T20:44:55Z","timestamp":1788813895731,"version":"build-2803163510"},"reference-count":44,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"AstraZeneca Greece"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"DOI":"10.1186\/s12885-025-14791-9","type":"journal-article","created":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T09:48:21Z","timestamp":1759312101000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Real-world management strategies and clinical outcomes of metastatic HER2-positive breast cancer in Greece in the second-line setting and beyond (the togetHER study)"],"prefix":"10.1186","volume":"25","author":[{"given":"Ippokratis","family":"Korantzis","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Koumarianou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vassiliki","family":"Rapti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eleni","family":"Timotheadou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christos","family":"Christodoulou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dimitrios","family":"Tryfonopoulos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sofia","family":"Karageorgopoulou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ioannis","family":"Boukovinas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Flora","family":"Zagouri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adamantia","family":"Nikolaidi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Konstantinos","family":"Papazisis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evangelia","family":"Razis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vasileios","family":"Barbounis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Athina","family":"Christopoulou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dimitrios","family":"Mavroudis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vassilios","family":"Georgoulias","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Georgios","family":"Kesisis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emmanuel I.","family":"Papadopoulos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rozalia","family":"Michalea","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandros","family":"Ardavanis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,10,1]]},"reference":[{"issue":"3","key":"14791_CR1","first-page":"209","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209\u201349.","journal-title":"CA Cancer J Clin"},{"key":"14791_CR2","unstructured":"Ferlay J, Ervik M, Lam F, Laversanne M, Colombet M, Mery L, Pi\u00f1eros M, Znaor A, Soerjomataram I, Bray F. Global cancer observatory: cancer today. lyon, france: international agency for research on cancer. Available from: https:\/\/gco.iarc.who.int\/today. Accessed 19 March 2024."},{"issue":"1","key":"14791_CR3","doi-asserted-by":"publisher","first-page":"982","DOI":"10.1186\/s12885-020-07449-1","volume":"20","author":"W Zhao","year":"2020","unstructured":"Zhao W, Wu L, Zhao A, Zhang M, Tian Q, Shen Y, Wang F, Wang B, Wang L, Chen L, et al. A nomogram for predicting survival in patients with de novo metastatic breast cancer: a population-based study. BMC Cancer. 2020;20(1):982.","journal-title":"BMC Cancer"},{"key":"14791_CR4","unstructured":"National Cancer Institute (NCI). Surveillance, Epidemiology, and End Results Program. Cancer Stat Facts: Female Breast Cancer. Available from: https:\/\/seer.cancer.gov\/statfacts\/html\/breast.html. Accessed 22 February 2024."},{"issue":"6","key":"14791_CR5","first-page":"524","volume":"72","author":"AN Giaquinto","year":"2022","unstructured":"Giaquinto AN, Sung H, Miller KD, Kramer JL, Newman LA, Minihan A, Jemal A, Siegel RL. Breast cancer statistics, 2022. CA Cancer J Clin. 2022;72(6):524\u201341.","journal-title":"CA Cancer J Clin"},{"issue":"16","key":"14791_CR6","doi-asserted-by":"publisher","first-page":"1659","DOI":"10.1056\/NEJMoa052306","volume":"353","author":"MJ Piccart-Gebhart","year":"2005","unstructured":"Piccart-Gebhart MJ, Procter M, Leyland-Jones B, Goldhirsch A, Untch M, Smith I, Gianni L, Baselga J, Bell R, Jackisch C, et al. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med. 2005;353(16):1659\u201372.","journal-title":"N Engl J Med"},{"issue":"2","key":"14791_CR7","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1056\/NEJMoa1113216","volume":"366","author":"J Baselga","year":"2012","unstructured":"Baselga J, Cortes J, Kim SB, Im SA, Hegg R, Im YH, Roman L, Pedrini JL, Pienkowski T, Knott A, et al. Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer. N Engl J Med. 2012;366(2):109\u201319.","journal-title":"N Engl J Med"},{"issue":"19","key":"14791_CR8","doi-asserted-by":"publisher","first-page":"1783","DOI":"10.1056\/NEJMoa1209124","volume":"367","author":"S Verma","year":"2012","unstructured":"Verma S, Miles D, Gianni L, Krop IE, Welslau M, Baselga J, Pegram M, Oh DY, Di\u00e9ras V, Guardino E, et al. Trastuzumab emtansine for HER2-positive advanced breast cancer. N Engl J Med. 2012;367(19):1783\u201391.","journal-title":"N Engl J Med"},{"issue":"5","key":"14791_CR9","doi-asserted-by":"publisher","first-page":"1236","DOI":"10.1016\/j.drudis.2021.12.021","volume":"27","author":"S Wang","year":"2022","unstructured":"Wang S, Yang Q, Deng L, Lei Q, Yang Y, Ma P, Men Y, Yung BC, Lee RJ, Zhang M, et al. An overview of cancer drugs approved through expedited approval programs and orphan medicine designation globally between 2011 and 2020. Drug Discov Today. 2022;27(5):1236\u201350.","journal-title":"Drug Discov Today"},{"issue":"12","key":"14791_CR10","doi-asserted-by":"publisher","first-page":"1623","DOI":"10.1016\/j.annonc.2020.09.010","volume":"31","author":"F Cardoso","year":"2020","unstructured":"Cardoso F, Paluch-Shimon S, Senkus E, Curigliano G, Aapro MS, Andr\u00e9 F, Barrios CH, Bergh J, Bhattacharyya GS, Biganzoli L, et al. 5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5). Ann Oncol. 2020;31(12):1623\u201349.","journal-title":"Ann Oncol"},{"issue":"12","key":"14791_CR11","doi-asserted-by":"publisher","first-page":"1475","DOI":"10.1016\/j.annonc.2021.09.019","volume":"32","author":"A Gennari","year":"2021","unstructured":"Gennari A, Andr\u00e9 F, Barrios CH, Cort\u00e9s J, de Azambuja E, DeMichele A, Dent R, Fenlon D, Gligorov J, Hurvitz SA, et al. Esmo clinical practice guideline for the diagnosis, staging and treatment of patients with metastatic breast cancer. Ann Oncol. 2021;32(12):1475\u201395.","journal-title":"Ann Oncol"},{"issue":"23","key":"14791_CR12","doi-asserted-by":"publisher","first-page":"2612","DOI":"10.1200\/JCO.22.00519","volume":"40","author":"SH Giordano","year":"2022","unstructured":"Giordano SH, Franzoi MAB, Temin S, Anders CK, Chandarlapaty S, Crews JR, Kirshner JJ, Krop IE, Lin NU, Morikawa A, et al. Systemic therapy for advanced human epidermal growth factor receptor 2-positive breast cancer: ASCO guideline update. J Clin Oncol. 2022;40(23):2612\u201335.","journal-title":"J Clin Oncol"},{"issue":"26","key":"14791_CR13","doi-asserted-by":"publisher","first-page":"2736","DOI":"10.1200\/JCO.2018.79.2697","volume":"36","author":"SH Giordano","year":"2018","unstructured":"Giordano SH, Temin S, Chandarlapaty S, Crews JR, Esteva FJ, Kirshner JJ, Krop IE, Levinson J, Lin NU, Modi S, et al. Systemic therapy for patients with advanced human epidermal growth factor receptor 2-positive breast cancer: ASCO clinical practice guideline update. J Clin Oncol. 2018;36(26):2736\u201340.","journal-title":"J Clin Oncol"},{"issue":"12","key":"14791_CR14","doi-asserted-by":"publisher","first-page":"1143","DOI":"10.1056\/NEJMoa2115022","volume":"386","author":"J Cort\u00e9s","year":"2022","unstructured":"Cort\u00e9s J, Kim S-B, Chung W-P, Im S-A, Park YH, Hegg R, Kim MH, Tseng L-M, Petry V, Chung C-F, et al. Trastuzumab deruxtecan versus trastuzumab emtansine for breast cancer. N Engl J Med. 2022;386(12):1143\u201354.","journal-title":"N Engl J Med"},{"issue":"10371","key":"14791_CR15","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1016\/S0140-6736(22)02420-5","volume":"401","author":"SA Hurvitz","year":"2023","unstructured":"Hurvitz SA, Hegg R, Chung WP, Im SA, Jacot W, Ganju V, Chiu JWY, Xu B, Hamilton E, Madhusudan S, et al. Trastuzumab deruxtecan versus trastuzumab emtansine in patients with HER2-positive metastatic breast cancer: updated results from DESTINY-Breast03, a randomised, open-label, phase 3 trial. Lancet (London, England). 2023;401(10371):105\u201317.","journal-title":"Lancet (London, England)"},{"issue":"1","key":"14791_CR16","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1056\/NEJMoa2203690","volume":"387","author":"S Modi","year":"2022","unstructured":"Modi S, Jacot W, Yamashita T, Sohn J, Vidal M, Tokunaga E, Tsurutani J, Ueno NT, Prat A, Chae YS, et al. Trastuzumab deruxtecan in previously treated HER2-low advanced breast cancer. N Engl J Med. 2022;387(1):9\u201320.","journal-title":"N Engl J Med"},{"issue":"23","key":"14791_CR17","doi-asserted-by":"publisher","first-page":"2610","DOI":"10.1200\/JCO.20.00775","volume":"38","author":"NU Lin","year":"2020","unstructured":"Lin NU, Borges V, Anders C, Murthy RK, Paplomata E, Hamilton E, Hurvitz S, Loi S, Okines A, Abramson V, et al. Intracranial efficacy and survival with tucatinib plus trastuzumab and capecitabine for previously treated HER2-positive breast cancer with brain metastases in the HER2CLIMB trial. J Clin Oncol. 2020;38(23):2610\u20139.","journal-title":"J Clin Oncol"},{"issue":"7","key":"14791_CR18","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1056\/NEJMoa1914609","volume":"382","author":"RK Murthy","year":"2020","unstructured":"Murthy RK, Loi S, Okines A, Paplomata E, Hamilton E, Hurvitz SA, Lin NU, Borges V, Abramson V, Anders C, et al. Tucatinib, trastuzumab, and capecitabine for HER2-positive metastatic breast cancer. N Engl J Med. 2020;382(7):597\u2013609.","journal-title":"N Engl J Med"},{"key":"14791_CR19","unstructured":"World Health Organization. The WHO Collaborating Centre for Drug Statistics Methodology. Available from: https:\/\/atcddd.fhi.no\/. Accessed 19 March 2024."},{"key":"14791_CR20","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14102468","author":"T Sanglier","year":"2022","unstructured":"Sanglier T, Fabi A, Flores C, Flahavan EM, Pena-Murillo C, Meyer AM, Montemurro F. T-DM1 after Pertuzumab plus Trastuzumab: treatment sequence-induced selection bias in HER2-positive metastatic breast cancer. Cancers. 2022. https:\/\/doi.org\/10.3390\/cancers14102468.","journal-title":"Cancers"},{"key":"14791_CR21","doi-asserted-by":"publisher","first-page":"175883592110598","DOI":"10.1177\/17588359211059873","volume":"13","author":"L Pizzuti","year":"2021","unstructured":"Pizzuti L, Krasniqi E, Sperduti I, Barba M, Gamucci T, Mauri M, Veltri EM, Meattini I, Berardi R, Di Lisa FS, et al. Panher study: a 20-year treatment outcome analysis from a multicentre observational study of HER2-positive advanced breast cancer patients from the real-world setting. Ther Adv Med Oncol. 2021;13:17588359211059872.","journal-title":"Ther Adv Med Oncol"},{"issue":"11","key":"14791_CR22","doi-asserted-by":"publisher","first-page":"1134","DOI":"10.1055\/a-1286-2917","volume":"80","author":"E Laakmann","year":"2020","unstructured":"Laakmann E, Emons J, Taran FA, Janni W, Uhrig S, Overkamp F, Kolberg HC, Hadji P, Tesch H, H\u00e4berle L, et al. Treatment landscape and prognosis after treatment with trastuzumab emtansine. Geburtshilfe Frauenheilkd. 2020;80(11):1134\u201342.","journal-title":"Geburtshilfe Frauenheilkd"},{"key":"14791_CR23","doi-asserted-by":"publisher","DOI":"10.3390\/cancers12103021","author":"LL Michel","year":"2020","unstructured":"Michel LL, Hartkopf AD, Fasching PA, Kolberg HC, Hadji P, Tesch H, H\u00e4berle L, Ettl J, L\u00fcftner D, Wallwiener M, et al. Progression-free survival and overall survival in patients with advanced HER2-positive breast cancer treated with trastuzumab emtansine (T-DM1) after previous treatment with pertuzumab. Cancers. 2020. https:\/\/doi.org\/10.3390\/cancers12103021.","journal-title":"Cancers"},{"issue":"3","key":"14791_CR24","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1177\/1078155220924088","volume":"27","author":"D Tataroglu Ozyukseler","year":"2021","unstructured":"Tataroglu Ozyukseler D, Basak M, Ay S, Koseoglu A, Ar\u0131c\u0131 S, Oyman A, S\u00fcrmeli H, Turan M, Turan N, Odaba\u015f H, et al. Prognostic factors of ado-trastuzumab emtansine treatment in patients with metastatic HER-2 positive breast cancer. J Oncol Pharm Pract Off Publ Int Soc Oncol Pharm Pract. 2021;27(3):547\u201354.","journal-title":"J Oncol Pharm Pract Off Publ Int Soc Oncol Pharm Pract"},{"issue":"2","key":"14791_CR25","doi-asserted-by":"publisher","first-page":"e181","DOI":"10.1016\/j.clbc.2019.09.001","volume":"20","author":"B Conte","year":"2020","unstructured":"Conte B, Fabi A, Poggio F, Blondeaux E, Dellepiane C, D\u2019Alonzo A, Buono G, Arpino G, Magri V, Naso G, et al. T-DM1 efficacy in patients with HER2-positive metastatic breast cancer progressing after a taxane plus pertuzumab and trastuzumab: an Italian multicenter observational study. Clin Breast Cancer. 2020;20(2):e181\u20137.","journal-title":"Clin Breast Cancer"},{"issue":"7","key":"14791_CR26","doi-asserted-by":"publisher","first-page":"1917","DOI":"10.1002\/ijc.32583","volume":"146","author":"L Pizzuti","year":"2020","unstructured":"Pizzuti L, Krasniqi E, Barchiesi G, Della Giulia M, Izzo F, Sanguineti G, Marchetti P, Mazzotta M, Giusti R, Botticelli A, et al. Distinct HR expression patterns significantly affect the clinical behavior of metastatic HER2+ breast cancer and degree of benefit from novel anti-HER2 agents in the real world setting. Int J Cancer. 2020;146(7):1917\u201329.","journal-title":"Int J Cancer"},{"key":"14791_CR27","doi-asserted-by":"publisher","first-page":"1621","DOI":"10.2147\/OTT.S191519","volume":"12","author":"R De Luca","year":"2019","unstructured":"De Luca R, Profita G, Cicero G. Nab-paclitaxel in pretreated metastatic breast cancer: evaluation of activity, safety, and quality of life. Onco Targets Ther. 2019;12:1621\u20137.","journal-title":"Onco Targets Ther"},{"issue":"34","key":"14791_CR28","doi-asserted-by":"publisher","first-page":"56921","DOI":"10.18632\/oncotarget.18176","volume":"8","author":"P Vici","year":"2017","unstructured":"Vici P, Pizzuti L, Michelotti A, Sperduti I, Natoli C, Mentuccia L, Di Lauro L, Sergi D, Marchetti P, Santini D, et al. A retrospective multicentric observational study of trastuzumab emtansine in HER2 positive metastatic breast cancer: a real-world experience. Oncotarget. 2017;8(34):56921\u201331.","journal-title":"Oncotarget"},{"issue":"5","key":"14791_CR29","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1097\/PPO.0000000000000144","volume":"21","author":"DA Yardley","year":"2015","unstructured":"Yardley DA, Krop IE, LoRusso PM, Mayer M, Barnett B, Yoo B, Perez EA. Trastuzumab emtansine (T-DM1) in patients with HER2-positive metastatic breast cancer previously treated with chemotherapy and 2 or more HER2-targeted agents: results from the T-PAS expanded access study. Cancer J (Sudbury, Mass). 2015;21(5):357\u201364.","journal-title":"Cancer J (Sudbury, Mass)"},{"key":"14791_CR30","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1016\/j.breast.2022.10.008","volume":"66","author":"T Sanglier","year":"2022","unstructured":"Sanglier T, Ross R, Shi T, Mouta J, Swain S, Cardoso F. Trastuzumab-based regimens beyond progression: a crucial treatment option for HER2+ advanced\/metastatic breast cancer. Breast (Edinburgh, Scotland). 2022;66:262\u201371.","journal-title":"Breast (Edinburgh, Scotland)"},{"issue":"7","key":"14791_CR31","doi-asserted-by":"publisher","first-page":"595","DOI":"10.2217\/cer-2020-0201","volume":"10","author":"SV Ramagopalan","year":"2021","unstructured":"Ramagopalan SV, Pisoni R, Zenin A, Rathore LS, Ray J, Sammon C. Comparative effectiveness of trastuzumab emtansine versus lapatinib plus chemotherapy for HER2+ metastatic breast cancer. J Comp Eff Res. 2021;10(7):595\u2013602.","journal-title":"J Comp Eff Res"},{"issue":"3","key":"14791_CR32","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1007\/s12094-019-02145-4","volume":"22","author":"J Gavil\u00e1","year":"2020","unstructured":"Gavil\u00e1 J, De La Haba J, Bermejo B, Rodr\u00edguez-Lescure \u00c1, Ant\u00f3n A, Ciruelos E, Brunet J, Mu\u00f1oz-Couselo E, Santisteban M, Rodr\u00edguez S\u00e1nchez CA, et al. A retrospective, multicenter study of the efficacy of lapatinib plus trastuzumab in HER2-positive metastatic breast cancer patients previously treated with trastuzumab, lapatinib, or both: the Trastyvere study. Clin Transl Oncol. 2020;22(3):420\u20138.","journal-title":"Clin Transl Oncol"},{"issue":"1","key":"14791_CR33","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1186\/s12885-019-5301-5","volume":"19","author":"A Kotsakis","year":"2019","unstructured":"Kotsakis A, Ardavanis A, Koumakis G, Samantas E, Psyrri A, Papadimitriou C. Epidemiological characteristics, clinical outcomes and management patterns of metastatic breast cancer patients in routine clinical care settings of Greece: results from the EMERGE multicenter retrospective chart review study. BMC Cancer. 2019;19(1):88.","journal-title":"BMC Cancer"},{"issue":"6","key":"14791_CR34","first-page":"657","volume":"28","author":"K DeBusk","year":"2022","unstructured":"DeBusk K, Ike C, Lindegger N, Schwartz N, Surinach A, Liu Y, Forero-Torres A. Real-world outcomes among patients with HER2+ metastatic breast cancer with brain metastases. J Manag Care Spec Pharm. 2022;28(6):657\u201366.","journal-title":"J Manag Care Spec Pharm"},{"issue":"4","key":"14791_CR35","doi-asserted-by":"publisher","first-page":"1431","DOI":"10.7314\/APJCP.2015.16.4.1431","volume":"16","author":"A Hedayatizadeh-Omran","year":"2015","unstructured":"Hedayatizadeh-Omran A, Rafiei A, Alizadeh-Navaei R, Tehrani M, Valadan R, Moradzadeh K, Panbechi M, Taghavi SM. Role of HER2 in brain metastasis of breast cancer: a systematic review and meta-analysis. Asian Pac J Cancer Prev APJCP. 2015;16(4):1431\u20134.","journal-title":"Asian Pac J Cancer Prev APJCP"},{"issue":"8","key":"14791_CR36","doi-asserted-by":"publisher","first-page":"2433","DOI":"10.1158\/1078-0432.CCR-18-2366","volume":"25","author":"SA Hurvitz","year":"2019","unstructured":"Hurvitz SA, O\u2019Shaughnessy J, Mason G, Yardley DA, Jahanzeb M, Brufsky A, Rugo HS, Swain SM, Kaufman PA, Tripathy D, et al. Central nervous system metastasis in patients with HER2-positive metastatic breast cancer: patient characteristics, treatment, and survival from SystHERs. Clin Cancer Res. 2019;25(8):2433\u201341.","journal-title":"Clin Cancer Res"},{"issue":"1","key":"14791_CR37","doi-asserted-by":"publisher","first-page":"e54","DOI":"10.1016\/j.clbc.2019.06.007","volume":"20","author":"AS Komorowski","year":"2020","unstructured":"Komorowski AS, Warner E, MacKay HJ, Sahgal A, Pritchard KI, Jerzak KJ. Incidence of brain metastases in nonmetastatic and metastatic breast cancer: is there a role for screening? Clin Breast Cancer. 2020;20(1):e54\u201364.","journal-title":"Clin Breast Cancer"},{"issue":"7","key":"14791_CR38","doi-asserted-by":"publisher","first-page":"e764","DOI":"10.1016\/j.clbc.2022.07.005","volume":"22","author":"I Tung","year":"2022","unstructured":"Tung I, Moldovan C, Wong V, De Boer R, Yeo B, Malik L, Greenberg S, Anton A, Nott L, Barnett F, et al. Real-world outcomes in patients with brain metastases secondary to HER2-positive breast cancer: an Australian multi-centre registry-based study. Clin Breast Cancer. 2022;22(7):e764\u201372.","journal-title":"Clin Breast Cancer"},{"issue":"5","key":"14791_CR39","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1016\/j.breast.2014.06.003","volume":"23","author":"C Jackisch","year":"2014","unstructured":"Jackisch C, Welslau M, Schoenegg W, Selbach J, Harich HD, Schr\u00f6der J, Schmidt M, G\u00f6hler T, Eustermann H, Ringel R, et al. Impact of trastuzumab treatment beyond disease progression for advanced\/metastatic breast cancer on survival\u2014results from a prospective, observational study in Germany. Breast (Edinburgh, Scotland). 2014;23(5):603\u20138.","journal-title":"Breast (Edinburgh, Scotland)"},{"issue":"1","key":"14791_CR40","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1186\/s12885-022-09556-7","volume":"22","author":"C Omarini","year":"2022","unstructured":"Omarini C, Piacentini F, Sperduti I, Cerma K, Barbolini M, Canino F, Nasso C, Isca C, Caggia F, Dominici M, et al. T-DM1 efficacy in trastuzumab-pertuzumab pre-treated HER2 positive metastatic breast cancer patients: a meta-analysis. BMC Cancer. 2022;22(1):623.","journal-title":"BMC Cancer"},{"issue":"1","key":"14791_CR41","doi-asserted-by":"publisher","first-page":"12760","DOI":"10.1038\/s41598-019-49251-5","volume":"9","author":"M Hardy-Werbin","year":"2019","unstructured":"Hardy-Werbin M, Quiroga V, Cirauqui B, Romeo M, Felip E, Teruel I, Garcia JJ, Erasun C, Espa\u00f1a S, Cucurull M, et al. Real-world data on T-DM1 efficacy\u2014results of a single-center retrospective study of HER2-positive breast cancer patients. Sci Rep. 2019;9(1):12760.","journal-title":"Sci Rep"},{"issue":"2","key":"14791_CR42","doi-asserted-by":"publisher","DOI":"10.1136\/esmoopen-2017-000176","volume":"2","author":"M Orditura","year":"2017","unstructured":"Orditura M, Gravina A, Riccardi F, Diana A, Mocerino C, Leopaldi L, Fabozzi A, Giordano G, Nettuno R, Incoronato P, et al. Eribulin for metastatic breast cancer (MBC) treatment: a retrospective, multicenter study based in Campania, south Italy (Eri-001 trial). ESMO Open. 2017;2(2): e000176.","journal-title":"ESMO Open"},{"issue":"10","key":"14791_CR43","doi-asserted-by":"publisher","first-page":"1283","DOI":"10.1016\/S1470-2045(20)30465-4","volume":"21","author":"LA Emens","year":"2020","unstructured":"Emens LA, Esteva FJ, Beresford M, Saura C, De Laurentiis M, Kim SB, Im SA, Wang Y, Salgado R, Mani A, et al. Trastuzumab emtansine plus atezolizumab versus trastuzumab emtansine plus placebo in previously treated, HER2-positive advanced breast cancer (KATE2): a phase 2, multicentre, randomised, double-blind trial. Lancet Oncol. 2020;21(10):1283\u201395.","journal-title":"Lancet Oncol"},{"issue":"1","key":"14791_CR44","doi-asserted-by":"publisher","first-page":"909","DOI":"10.1186\/s12885-019-6126-y","volume":"19","author":"B Daniels","year":"2019","unstructured":"Daniels B, Kiely BE, Tang M, Tervonen H, Pearson SA. Trastuzumab use in older patients with HER2-positive metastatic breast cancer: outcomes and treatment patterns in a whole-of-population Australian cohort (2003\u20132015). BMC Cancer. 2019;19(1):909.","journal-title":"BMC Cancer"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-025-14791-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12885-025-14791-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-025-14791-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T09:48:23Z","timestamp":1759312103000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmccancer.biomedcentral.com\/articles\/10.1186\/s12885-025-14791-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,1]]},"references-count":44,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["14791"],"URL":"https:\/\/doi.org\/10.1186\/s12885-025-14791-9","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,1]]},"assertion":[{"value":"24 January 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 August 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 October 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The present study was designed, conducted and reported in accordance with the ethical principles laid down in the Declaration of Helsinki, the Guidelines for Good Pharmacoepidemiology Practice of the International Society for Pharmacoepidemiology, the STROBE (Strengthening the Reporting of Observational Studies in Epidemiology) guidelines where applicable, the EU General Data Protection Regulation, and the local rules and regulations. In compliance with the latter, the final protocol of this Observational Study, including the final version of the Subject ICF, along with any amendments have been approved in writing by the Institutional Review Board of each participating hospital. National Ethics Committee (NEC) approval was waived based on local legislation. Informed consent was obtained from all individual participants included in the study except for deceased patients for whom a waiver of consent has been granted by the Institutional Review Board of each study site.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Ippokratis Korantzis, Anna Koumarianou, Vassiliki Rapti, Adamantia Nikolaidi, Vasileios Barbounis, Athina Christopoulou, Dimitrios Mavroudis, Vassilios Georgoulias, Georgios Kesisis, and Alexandros Ardavanis have no relevant financial or non-financial interests to disclose; Eleni Timotheadou has received research funding and honoraria from Roche, AstraZeneca, Amgen, Genesis, Pfizer, GSK, MSD, Novartis; Christos Christodoulou declared financial or non-financial interest with Amgen, AstraZeneca, BMS, Genesis, Gilead, Lilly, Merck, MSD, Novartis, Pfizer, Roche; Dimitrios Tryfonopoulos has received honoraria from Roche, AstraZeneca, Genesis-pharma; Sofia Karageorgopoulou has received honoraria for satellite lectures\/advisory boards and research compensation and\/or conference registration fees and travel grants from Amgen, AstraZeneca, Gilead Sciences, Genesis Pharma, GlaxoSmithKline, MSD, Novartis, Pfizer, Roche, Teva; Ioannis Boukovinas has received honoraria from Roche, MSD, Bristol-Myers Squibb, Pfizer, Novartis, Merck, AstraZeneca, LEO Pharma, Servier, consulting or advisory role fees from Roche, Sanofi, AstraZeneca, Bristol-Myers Squibb, LEO Pharma, MSD, Novartis, Ipsen, Genesis Pharma, research funding from Roche, Novartis, Bristol-Myers Squibb, MSD, Regeneron, Boehringer Ingelheim, Lilly, Pfizer, and travel, accommodations, expenses support from MSD, Roche, Pfizer, Bristol-Myers Squibb; Flora Zagouri has received honoraria for lectures and has served in an advisory role for AstraZeneca, Daiichi, Eli- Lilly, Merck, Novartis, MSD, Pfizer, Genesis- Pharma and Roche; Konstantinos Papazisis has received honoraria and consultancy fees from MSD, Gilead, AstraZeneca, Novartis, Genesis, IPSEN, Eli Lilly, Roche and GSK, research funding from Roche, MSD, Novartis, Daiichi Sankyo, Eli Lilly, Nektar, AstraZeneca, BMS, Sanofi, Boehringer and EISAI; Evangelia Razis has received travel grants from BMS, Roche, Pfizer, Karyo, Gilead Sciences and Genesis Pharma. Furthermore, Dr Razis has received honoraria from Servier pharmaceuticals and research funding from Tesaro, IQvia, AstraZeneca, Exelixis, PPD Global and MSD. Dr Razis has served in consulting\/advisory role for AstraZeneca; Emmanuel I Papadopoulos and Rozalia Michalea are employees of AstraZeneca Greece. The Study was designed collaboratively by the Sponsor and Investigators. The sponsor had no involvement in the collection, analysis, and interpretation of data. A Medical writing vendor was used and paid by the sponsor to compose the first draft of the manuscript which was reviewed and approved by all authors who unanimously made the decision to submit the manuscript for publication.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"1473"}}